Overlap syndromes in autoimmune liver disease: a review.

IF 3.8 Q2 GASTROENTEROLOGY & HEPATOLOGY
Translational gastroenterology and hepatology Pub Date : 2025-04-15 eCollection Date: 2025-01-01 DOI:10.21037/tgh-24-140
Aalam Sohal, Nikki Nikzad, Kris V Kowdley
{"title":"Overlap syndromes in autoimmune liver disease: a review.","authors":"Aalam Sohal, Nikki Nikzad, Kris V Kowdley","doi":"10.21037/tgh-24-140","DOIUrl":null,"url":null,"abstract":"<p><p>Self-directed immune-mediated injury to hepatocytes and cholangiocytes results in autoimmune liver disease (AILD). AILD comprises three distinct entities: autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC) and each of these autoimmune conditions has distinct phenotypic, serological, radiologic and laboratory findings. AIH is characterized by injury to the hepatocytes while PBC and PSC occur due to injury to bile ducts. Although, these are considered rare diseases, it is important to note that some patients can present with features characteristic of more than one AILD, and these conditions are described as overlap syndromes (OS). Currently, there is lack of data regarding the epidemiology of OS. Majority of the data regarding the epidemiology of OS comes from single-center and small studies. The clinical features of OS are similar to the underlying AILD. There is also no consensus on how to manage patients with OS and the management is dependent on treating the underlying AILDs. Management of PBC involves use of ursodeoxycholic acid (UDCA), while management of AIH involves the use of steroids and immunosuppressants. In this article, we will review the current literature on various OS and their respective diagnostic criteria. This article will also discuss epidemiology, clinical features, prognosis as well as outcomes among patients with various OS.</p>","PeriodicalId":94362,"journal":{"name":"Translational gastroenterology and hepatology","volume":"10 ","pages":"33"},"PeriodicalIF":3.8000,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12056124/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational gastroenterology and hepatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21037/tgh-24-140","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Self-directed immune-mediated injury to hepatocytes and cholangiocytes results in autoimmune liver disease (AILD). AILD comprises three distinct entities: autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC) and each of these autoimmune conditions has distinct phenotypic, serological, radiologic and laboratory findings. AIH is characterized by injury to the hepatocytes while PBC and PSC occur due to injury to bile ducts. Although, these are considered rare diseases, it is important to note that some patients can present with features characteristic of more than one AILD, and these conditions are described as overlap syndromes (OS). Currently, there is lack of data regarding the epidemiology of OS. Majority of the data regarding the epidemiology of OS comes from single-center and small studies. The clinical features of OS are similar to the underlying AILD. There is also no consensus on how to manage patients with OS and the management is dependent on treating the underlying AILDs. Management of PBC involves use of ursodeoxycholic acid (UDCA), while management of AIH involves the use of steroids and immunosuppressants. In this article, we will review the current literature on various OS and their respective diagnostic criteria. This article will also discuss epidemiology, clinical features, prognosis as well as outcomes among patients with various OS.

自身免疫性肝病重叠综合征的研究进展
自体免疫介导的肝细胞和胆管细胞损伤可导致自身免疫性肝病(AILD)。AILD包括三种不同的实体:自身免疫性肝炎(AIH)、原发性胆汁性肝硬化(PBC)和原发性硬化性胆管炎(PSC),这些自身免疫性疾病中的每一种都有不同的表型、血清学、放射学和实验室结果。AIH的特点是肝细胞损伤,而PBC和PSC的特点是胆管损伤。虽然这些被认为是罕见的疾病,但重要的是要注意,一些患者可以表现出不止一种AILD的特征,这些情况被称为重叠综合征(OS)。目前,关于OS的流行病学数据缺乏。大多数关于OS流行病学的数据来自单中心和小型研究。OS的临床特征与潜在的AILD相似。对于如何管理OS患者也没有共识,管理依赖于治疗潜在的aild。PBC的治疗包括使用熊去氧胆酸(UDCA),而AIH的治疗包括使用类固醇和免疫抑制剂。在本文中,我们将回顾目前关于各种OS及其各自诊断标准的文献。本文还将讨论各种OS患者的流行病学、临床特征、预后以及预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信